Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
1.240
+0.040 (3.33%)
Oct 24, 2025, 4:00 PM EDT - Market closed

Liminatus Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
1.740.651.060.860.2
Research & Development
0.362.693.761.853.8
Operating Expenses
2.093.334.822.714
Operating Income
-2.09-3.33-4.82-2.71-4
Interest Expense
-0.38-0.34-0.18-0.22-1.61
Interest & Investment Income
0.160.120.01--
Pretax Income
-1.05-3.55-4.98-2.93-5.61
Net Income
-1.05-3.55-4.98-2.93-5.61
Net Income to Common
-1.05-3.55-4.98-2.93-5.61
Shares Outstanding (Basic)
11411210236-
Shares Outstanding (Diluted)
11411210236-
Shares Change (YoY)
28.19%9.49%188.25%--
EPS (Basic)
-0.01-0.03-0.05-0.08-
EPS (Diluted)
-0.01-0.03-0.05-0.08-
EBITDA
----2.71-4
D&A For EBITDA
---00
EBIT
-2.09-3.33-4.82-2.71-4
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q